arrow
D

Daniel J. Powell

Perelman School of Medicine
H指数:57
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection

模块化 γ δ tcr-t平台,将KRAS pMHC靶向与可重复剂量的mRNA接合器重定向相结合

2026-07-300
OA
GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia

符合GMP标准的同种异体外周血CAR-NK细胞治疗急性髓系白血病的制造

2025-11-160
OAAI
A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors

一种基于CRISPR/Cas9技术的早期记忆性同种异体NKG2D CAR-T细胞疗法用于实体瘤的新型疗法

2025-09-300
OAAI
Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors
2024-09-170
OAAI
CD5 deletion enhances the antitumor activity of adoptive T cell therapies

CD5缺失增强过继性T细胞疗法的抗肿瘤活性

2024-07-195
PRE
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer
2023-09-218
PRE
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)
2023-07-203
OAAI
INCA33890, a novel PD-1xTGF.R2 bispecific antibody conditionally antagonizes TGFβ signaling in primary immune cells co- expressing PD-
2023-04-041
PRE
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

高危神经母细胞瘤astatine-211-parthanatine的临床前研究

2022-11-1710
OAAI
Epigenetic state determines inflammatory sensing in neuroblastoma

表观遗传状态决定神经母细胞瘤的炎症感知

2022-02-0428
OAAI
FIRST-IN-HUMAN PHASE I CLINICAL TRIAL EVALUATING INTRAPERITONEAL ADMINISTRATION OF MOV19-BBZ CAR T CELLS IN PATIENTS WITH ALPHA FOLATE RECEPTOR-EXPRESSING RECURRENT HIGH GRADE SEROUS OVARIAN CANCER
2021-11-103
OA